BYMA incorporates a new Marketable Security in the SVS Bond Panel

BYMA adds a new marketable security to its Panel of green, social and/or sustainable bonds. The objective of Richmond Laboratories' Project VIDA Financial Trust is to finance the acquisition, installation and start-up of a plant for the production of vaccines, including those established against the SARS-CoV-2 coronavirus (COVID-19). The issue of the Project VIDA Financial Trust - Richmond Laboratories is aligned with the four components of ICMA's Sustainable Bond Principles (Bonds with positive environmental and social impact aligned to the GBP and SBP), generating a positive environmental and social impact.According to the External Review, the project has a direct positive social impact through improved access to medicines by ensuring greater availability of the finished product (vaccines) and contributing to the self-sufficiency of national production, job creation, personnel training and socioeconomic progress, and a positive environmental impact through the incorporation of the LEED standard in the construction stage.The development of this new SVS instrument also has the potential to contribute to the SDGs of Health and Wellness, Decent Work and Economic Growth and Reducing Inequalities. Responsible Production and Consumption and Climate Action. "We continue to support the promotion of sustainable finance by encouraging the formation of marketable securities that comply with SVS attributes. This Panel allows issuers to have additional visibility from placement through BYMA's system, BYMA PRIMARIAS, as in the listing and until full redemption where all the information on the review, use of funds and benefits obtained year by year is available." added the president of BYMA, Ernesto Allaria. "It is gratifying that we have been able to finance the first biotechnology project open to the local market through a sustainable bond. Our commitment to the environment and our community is central to our business strategy. In this regard, we are proud that the US$85 million investment in the biotech plant will improve access to biotech therapies in Argentina and the region, develop local human capital, contribute to the development of our community in Pilar and care for the environment," said Marcelo Figueiras, President of Laboratorios Richmond For the Comisión Nacional de Valores (CNV), this is a case that we seek to multiply in order to put the capital market at the service of financing destinations for diverse sectors of the economy and productive activity throughout the country,Adrián Cosentino as highlighted by the agency's president, Adrián Cosentino.The official highlighted "the great expectation" generated by the approval of the Fideicomiso Financiero (FF) VIDA in all market players, "even more because it is a transaction that will allow connecting investors with a sustainable bond, on which we have been working very hard at the CNV".More information on the SVS Bond Panel